AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.